Analysis Shows Better Integration Needed Between and Drugs@FDA

Analysis Shows Better Integration Needed Between and Drugs@FDA
Analysis Shows Better Integration Needed Between and Drugs@FDA

Although Drugs@FDA may be useful for validating trial primary outcomes found on, it was far less useful for validating secondary outcomes and information about adverse events, including deaths. This finding is based on an analysis of data from 100 trials available on both websites.1

The comparison was funded by the National Library of Medicine and led by Lisa Schwartz, PhD, and Steven Woloshin, PhD, from The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire.

Primary outcomes are the answer to the most important question asked by a trial, and may report whether a new treatment is more effective than existing therapies. Secondary outcomes address other relevant questions related to the study, such as the effect on the overall cost of treatment or the impact on quality of life.

All primary outcome measures posted on were matched with publically available data from Drugs@FDA in the study sample and were found to be largely consistent. In contrast, only approximately half (51%) of the secondary outcomes listed on were identified at Drugs@FDA. Serious adverse events and deaths also could not be validated for most trials because Drugs@FDA typically only reports such data aggregated across trials.

The researchers concluded that better integration between the 2 sites is needed. Even if all the numbers reported in were completely accurate, information on the trial design, conduct, or analysis would be incomplete and could affect conclusions about the trial results assessed in Drugs@FDA.


1. Schwartz LM, Woloshin S, Zheng E, et al. and Drugs@FDA: A comparison of results reporting for new drug approval trials. Ann Intern Med. 2016 Jun 14. doi:10.7326/M15-2658. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs